Dong-A signs DA-9701 export deals

Published: 2011-04-01 06:58:00

Updated: 2011-04-01 06:58:00

Dong-A Pharmaceutical Co. said Wednesday that it has inked a memorandum of understanding with Pahang (Malaysia) and Landson (Indonesia) for its in-house developed DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber.

The terms and conditions of the deal have yet...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK